R&D Allocationv3 · 09.07
Whose research opportunities follow compute investment?
A collaboration route exists from Japan. Check funding, compute allocation, disclosure and IP conditions.
- ✓Open callRecorded
- ◷AwardsScheduled
- ◷StartScheduled
- ?OutcomesUnverified
Additional source checkedUpdated the related analysis after further source checks. This is not a newly announced trial or experiment.
NEXT CHECKCheck eligibility, collaborators, compute allocations, publication and IP terms. Deadline: December 1 at noon ET; decisions scheduled for March 1, 2027.
R&D Allocationv2 · 09.07
How far can measurement resolve a question about memory?
CLEM used in the same study. Observation is not intervention.
- ✓Method usedRecorded
- ✓Structure linkedRecorded
- ?TransferUnverified
- ?AdoptionUnverified
Analysis addedAdded a short reading on what CLEM measures, reuse of the method, and its combination with activity recording and intervention.
NEXT CHECKMethod reuse, implementations in other studies and the skills and equipment required.
R&D Allocationv1 · 09.23
Who checks clinical AI decisions, and how is that supervision itself evaluated?
ARPA-H announced ADVOCATE development plans covering patient-facing AI, supervision, implementation and independent evaluation.
- ✓Program and awardsRecorded
- ?DevelopmentUnverified
- ?Clinical evaluationUnverified
- ?AuthorizationUnverified
New question openedPublished the analysis and recorded the next checks.
NEXT CHECKMissed errors, false alarms, appropriate clinical handoffs and evaluation in routine care.
R&D Allocationv1 · 09.29
Can cells retain their function through room-temperature storage and transport?
BoSS announced three development teams and independent testing by ATCC, with up to $87 million planned over four years.
- ✓Reports and agreements reviewedRecorded
- ?Further validationUnverified
- ?Adoption and benefitUnverified
New question openedRecorded a new question and follow-up checks from the approved manuscript.
NEXT CHECKStorage duration by cell type, recovered function and independent ATCC testing.
R&D Allocationv1 · 10.09
Who pays for the work of making AI-enabled trials viable, and what do they buy?
SURPASS calls for validation in real trials, with initial public support and a route to continuing operations. Participation does not establish an automatic allocation of drug development or commercial rights.
- ✓Reports and agreements reviewedRecorded
- ?Further validationUnverified
- ?Adoption and benefitUnverified
New question openedExamine continuing operations and payment for AI-enabled trials through the SURPASS solicitation.
NEXT CHECKSelected teams, trial execution, payment by later sponsors and terms for model and patient-data use.
R&D Allocationv1 · 10.13
How reliably can research AI lead to antibody candidates that meet the requirements of a particular application?
A common-condition study of 511 sequences from 29 organizations found different performance in improvement and ranking tasks. Cradle’s high-affinity candidate passed the aggregate threshold but retained concerns in individual developability assays.
- ✓Blinded comparison under common conditionsRecorded
- ?Compare application-specific requirementsUnverified
- ?Reproducibility across targetsUnverified
New question openedDistinguished antibody design, selection and development decisions, and recorded aggregate scoring alongside individual concerns.
NEXT CHECKReproducibility across targets, yield of candidates meeting required conditions, synthesis and assay counts, and cost and time to a development decision.
R&D Allocationv1 · 10.19
Can comparing skin and lung fibrosis provide evidence for deciding which diseases to pursue with a drug?
3D-MOFIB plans to begin with scleroderma and pulmonary fibrosis associated with Hermansky–Pudlak syndrome, screening compounds and molecular activity in patient-derived models to explore shared fibrosis mechanisms and organ-specific differences.
- ✓Research plan describedRecorded
- ?Test shared and distinct responsesUnverified
- ?Inform indication selectionUnverified
New question openedRecord a research plan to use shared fibrotic processes and organ differences in indication selection.
NEXT CHECKCandidates with shared responses across skin and lung models, conditions that separate responses, reproducibility across donor samples and subsequent development decisions.
R&D Allocationv1 · 10.24
Can a model learn intervention–response relationships and predict responses in unmeasured cellular conditions?
The Virtual Biology Initiative expands joint experimental-data infrastructure. Separately, Arc’s 2026 challenge tests response prediction without providing perturbation outcomes in the target cells.
- ✓Shared infrastructure expandedRecorded
- ?Add perturbation dataUnverified
- ?Evaluate unseen conditionsUnverified
New question openedRecord investment in shared experimental data separately from evaluation in unseen conditions.
NEXT CHECKAdded cells and interventions, independently evaluated predictive performance, and data-release and reuse conditions.